


DIGNITANA

Clinically superior scalp cooling

AUGUST 19 • 2021

**US treatment growth
drives 23 percent
increase in net revenue**



Q2 21

QUARTERLY REPORT

US treatment growth drives 23 percent increase in net revenue

Financial highlights Q2 2021

- Net sales amounted to 14 MSEK (11,4), an increase of 23 percent over the same period 2020.
- Operating result amounted to -9,4 MSEK (-9,0)
- Net result after financial items amounted to -9,7MSEK (-9,5)
- Earnings per share were -0,15 SEK (-0,17)
- Cash Balance amounted to 36,3 MSEK (7,5)
- Average Daily Treatment Revenue (ADTR)* was 163 TSEK (109), an increase of 49 percent over the same period in 2020.

Financial highlights January – June 2021

- Net sales amounted to 27,2 MSEK (22,8), an increase of 19 percent over the same period 2020.
- Operating result amounted to -16,5 MSEK (-21,5)
- Net result after financial items amounted to -17,3 MSEK (-22,3)
- Earnings per share were -0,28 SEK (-0,40)
- Cash Balance amounted to 36,3 MSEK (7,5)
- Average Daily Treatment Revenue (ADTR)* was 146 TSEK (106), an increase of 38 percent over the same period in 2020.

Significant events during the period

- The Annual General Meeting was held in Lund in May and resolved all proposed items in accordance with the announced proposals.
- In April Dignitana published the Annual Report for 2020.

Business highlights during the period

- Dignitana-backed insurance legislation in Texas did not come to a full vote prior to the close of the session in May.

Business highlights after the period

- In June Dignitana launched new initiatives to support reimbursement and market access in the US.
- Dignitana signed distributor B&Co Group to support Benelux Growth in July.
- The Board of Directors has appointed The Chairman of the Board Klas Arildsson to the role of a working Chairman supporting growth from an operational point of view. He will focus on Quality and Regulatory Affairs and operational efficiency.

"Dignitana continues our growth trajectory, and the second period of the year provides solid evidence of the progress we are making."

William Cronin, CEO Dignitana AB

Key Figures

DIGNITANA GROUP	Q2 2021	Q2 2020	Q1-Q2 2021	Q1-Q2 2020	Full year 2020
Net sales, TSEK	14 038	11 423	27 203	22 816	46 629
Total revenues, TSEK	17 174	11 876	31 331	24 353	49 956
Net profit after financial items, TSEK	-9 660	-9 528	-17 324	-22 283	-52 963
Cash and bank balances, TSEK	36 333	7 484	36 333	7 484	78 770
Earnings per share before and after dilution, SEK	-0,15	-0,17	-0,28	-0,40	-0,96
Average Daily Treatment Revenue,* TSEK	163	109	146	106	120

* ADTR includes pay-per-treatment revenue from patients and facilities in the U.S. Does not include lease revenue or disposable sales.

DIGNITANA AB IS A SWEDISH MEDICAL TECHNOLOGY COMPANY THAT PRODUCES AND MARKETS THE DIGNICAP SCALP COOLING SYSTEM TO MINIMIZE HAIR LOSS DURING CHEMOTHERAPY AND IMPROVE WELL-BEING AND QUALITY OF LIFE FOR CANCER PATIENTS.

US treatment growth drives 23 percent increase in net revenue

Dignitana continues our growth trajectory, and the second period of the year provides solid evidence of the progress we are making. The company posted a 23 percent increase in net revenue for the Group since the second period 2020. Additionally, during this period, we have seen a 49 percent increase in Average Daily Treatment Revenue (ADTR), our key U.S. metric for frequency of device use. The company's ability to post these numbers is testament to not only the discipline we have stuck to as the pandemic has continued to impact our normal operating procedures, but also to the expanding awareness and interest in scalp cooling from both patients and providers. Dignitana has made significant progress this year, but we still have much work to do. Posting these numbers is quite an accomplishment, and I am pleased with our advances on multiple fronts, especially considering the ongoing uncertainties in the business climate and healthcare category specifically over the past 17 months from the pandemic.

US growth leads the Company

We now have more than 250 locations across 34 states in the US. Availability of DigniCap continues to expand into new markets and the DigniCap Delta is now available at multiple locations in many of our demographically targeted major metropolitan areas. Over 330 DigniCap Delta devices have been deployed in the US since the next generation device was launched in Q3 2019. Each new facility and market we enter helps to generate greater awareness and acceptance of this vital therapy option. The pace of contract signings has accelerated this period, including agreements with several prominent health care providers. Our growth strategy places a heavy emphasis on key partnerships with multi-site providers and group purchase organizations. One example of a recently launched industry partnership has yielded 16 new Delta locations for the company since it was introduced in March 2021.

Building momentum with reimbursement infrastructure

Reimbursement is the single biggest regulatory development for scalp cooling since our device was first cleared in December 2015. Two new Category III Current Procedural Terminology (CPT®) codes for mechanical scalp cooling became effective on July 1st. This does not mean that all insured patients now have coverage for the treatment, but the introduction of these new codes is an exceptionally large step toward scalp cooling becoming standard of care in the US market as it already is in several overseas markets. With the National Comprehensive Cancer Network® (NCCN®) and the Oncology Nursing Society providing clinical recommendations for scalp cooling and the effectiveness of the new CPT codes, we are working extremely hard to help make this therapy available to as many patients as possible in the future.

In June we launched the DigniCap Reimbursement Hub to support providers and patients throughout the reimbursement process. The creation of this infrastructure is critical in navigating the complex process of establishing reimbursement and coverage levels with payors. This process takes time, but we are making progress and helping payors see the value and importance of this therapy option as utilization increases.

Targeted global growth

The Company is maintaining our primary focus on the all-important US market. We also are pursuing several targeted growth initiatives on the global stage with opportunities in Europe, Asia and Australia. In light of COVID-19 protocols, many of these regions are particularly keen on the infection control benefits presented by DigniCap Delta's single-patient cap system.

Quality and Regulatory Affairs enhancements support product excellence and growth

During the second period the Company expanded our Quality and Regulatory Affairs teams in order to take full advantage of the evolving global opportunities mentioned above. These one-time costs for improvements and additional resources ensure that we are effectively and proactively addressing all regulatory requirements for those markets we presently are active in and those we are looking to enter.

Consistent performance

Looking back at the Company's performance throughout the pandemic I am incredibly proud of our accomplishments in operational efficiencies, financial performance, and key metrics. This progress is a testament to the continued support of our shareholders and the talented and passionate individuals who have worked tirelessly to bring us this far – work that continues as we strive to make scalp cooling standard of care worldwide.



A handwritten signature in blue ink that reads "William Cronin".

William Cronin, CEO
Dignitana AB

The Company

Dignitana AB is a medical technology company based in Lund, Sweden and publicly traded on Nasdaq First North Growth Market in Sweden. Company headquarters are in Lund, Sweden and operations are based in Dallas, Texas in the United States. Company subsidiaries are Dignitana, Inc. in the United States and Dignitana S.r.l. in Italy. Redeye AB is Certified Adviser.


The Company produces the DigniCap Scalp Cooling System, a patented medical cooling device that offers cancer patients the ability to minimize hair loss during chemotherapy to improve well-being and quality of life. The DigniCap Scalp Cooling System was invented in 1999 by a Swedish oncology nurse.

DigniCap has been on the market in Europe since 2001 and has had FDA clearance since 2015 to provide continuous scalp cooling with high efficacy, safety, and acceptable patient comfort. In 2017 Dignitana received expanded clearance from the FDA allowing DigniCap to be used by patients receiving chemotherapy to treat solid tumors from breast cancer as well as those from prostate, ovarian, uterine, lung and other tissues. In 2019 Dignitana received CE Marking and FDA clearance for sales of DigniCap Delta, the next generation scalp cooling device, followed by approvals for the new model in Australia and Israel.

Business model

Dignitana has two business models: in the United States devices are leased and the Company receives payments for each treatment. Outside the U.S. devices are sold to facilities and the company also receives revenue from service and maintenance agreements. The introduction of the DigniCap Delta system has added an additional revenue stream from consumables to both models with sales of the single-patient DigniCap Delta caps and patient kits. The largest opportunity for growth is through the pay-per-treatment model as utilized in the United States.

For global markets that do not have the pay-per-treatment model, the focus is on creating a more sustainable recurring revenue stream from unit sales, lease agreements, service and maintenance fees, and sales of product disposables and supplies. The new, single patient, DigniCap Delta is generating significant additional interest from the medical community, and we believe the trend towards greater infection control standards will generate additional momentum for the Company going forward.



The market

The market

DigniCap minimizes chemotherapy-induced hair loss for cancer patients with solid tumors. Globally there are over 12 million incidences of solid tumors diagnosed annually, with more than 1,8 million diagnoses occurring in the U.S. each year. Dignitana estimates that 60 percent of these patients are on regimens compatible with DigniCap. Scalp cooling is primarily used today during the treatment of breast cancer, the most common type of cancer in women worldwide with over 1,7 million cases of breast cancer diagnosed annually. Scalp cooling is also used by patients with other solid tumors such as ovarian, uterine, endometrial, cervical, and prostate cancers.

To increase awareness of scalp cooling we work strategically with different organizations and interest groups in the cancer care community. Dignitana's ongoing sponsorship of Susan G. Komen, the largest breast cancer advocacy group in the world, is an example of this. In most of the world scalp cooling is not a standard option for cancer care. The acceptance, market penetration and utilization of this treatment vary widely, providing significant opportunities for Dignitana all over the world.

Dignitana is committed to advancing the science of scalp cooling by supporting clinical trials and research initiatives among DigniCap users. The Company is currently in discussions to initiate several new studies that could expand usage to new user groups and show improvements with existing regimens that have exhibited inferior results with scalp cooling previously.

Market development

The DigniCap Scalp Cooling System is clinically proven to reduce hair loss in cancer patients undergoing chemotherapy for solid tumors. The DigniCap Scalp Cooling System has been marketed worldwide since 2009 and received FDA clearance for the US market in 2015. The DigniCap Delta model was introduced in 2019 and is a smaller, single-patient device providing optimal outcomes and improved ease of use for clinicians and patients. In 2019 DigniCap Delta received CE Marking for Europe and FDA clearance for the U.S., followed by TGA clearance for Australia.



Financial information and comments

DIGNITANA GROUP

Revenues

Group revenues are generated by direct sales of systems, leased systems, pay-per treatment fees, revenues from service and maintenance agreements, sales of individual caps and kit accessories. For the second quarter 2021 net sales amounted to 14 038 TSEK (11 423), an increase over the same period 2020 by 2 615 TSEK or 23 percent. YTD net sales reached 27 203 TSEK (22 816) and increase of 4 387 TSEK or 19 percent.

The Payroll Protection Program Loan, obtained by Dignitana Inc in 2020, has been wholly forgiven, thereby 2 994 TSEK has been recognized under other income during the quarter.

Dignitana operates by two business models: in the U.S. market DigniCap Delta systems are leased out and the Company gains revenues from leasing fees and payment for treatments. Outside the U.S, revenues are generated by DigniCap Delta systems being sold, frequently combined with service and maintenance agreements. In addition to this, the Company also has revenues from the sale of individual caps as well as consumables and accessories.

The U.S. market continues to be the driver in the transition to DigniCap Delta and a revised business model. During the quarter, 18 new DigniCap Delta units were installed, which yielded a total installed base of 330 devices.

Dignitana's revenue and costs comprise of different currencies such as USD, EUR, and SEK. operational exchange rate effects are recognized in the income statement either under other operating income or other operating expenses depending on the net effect. In the second quarter 2021 net exchange effects amounted to - 595 TSEK (-1 000) and YTD net exchange effects were 385 TSEK (-572). Exchange rate effects on financial holdings are recognized under other interest income and similar items and were for the second quarter -40 TSEK (-105), YTD 16 TSEK (-113)

Operating Expenses and Operating Result

Operating expenses increased during the quarter compared to the same period last year by 5 681 TSEK and amounted to -26 586 TSEK (-20 905) and YTD -47 875 TSEK (-45 864). The increase relates to expanding business activities, but also, as a result of the focused efforts to strengthen Quality and Regulatory Management within the Company, external costs are up during the quarter. Travelling and marketing costs are at moderate levels, while personnel costs have gone up given additional headcount in our US operations.

Depreciation and amortization in the Group amounted to -2 972 TSEK (-3 964), YTD -6 278 TSEK (-7 683).

The operating result after depreciation for the Group amounted to -9 412 TSEK (-9 030) and decline over the same period 2020 of 382 TSEK. Operating loss YTD amounted to -16 544 TSEK (-21 511).

Financial net

Financial net was -248 TSEK (-498), with corresponding YTD numbers -780 TSEK (-772) and consists mainly of interest paid on loans.

Employees

Number of employees is 28 (26).

Cash Flow and Financial Position

Consolidated cash flows from operating activities during the quarter was -14 408 TSEK (-1 341), YTD -23 105 TSEK (-11 504). Cash and cash equivalents at the end of the quarter amounted to 36 333 TSEK (7 484).

CAPEX

Capex which amounted to 2 807 TSEK (3 627) in the quarter and YTD 4 907 TSEK (11 113), mainly relates to DigniCap Delta devices.

DIGNITANA PARENT COMPANY

Revenues

Total revenues the first quarter was 9 648 TSEK (7 600). Other income is attributable to exchange rate effects.

Operating Expenses and Operating Result

Operating expenses increased during the quarter compared to the same period last year by 1 560 TSEK and amounted to -13 794 TSEK (-12 234).

Operating result was -4 138 TSEK (-4 014) and net result for the period was - 4 177 TSEK (-4 121)

The share

Dignitana is listed on First North Growth Market since November 2011 after having been listed on Spotlight Market in Stockholm since June 2009.

Dignitana AB

TICKER	DIGN
Market Cap	484 MSEK
Number of shareholders, approximately	2 594
Share price June 30	7,44 SEK
Number of shares traded during the quarter	2 291 910
Number of shares outstanding June 30	65 059 155
Registered share capital	6 505 916 SEK
Par value	0,1 SEK
Certified Adviser	Redeye

Dignitana has only one category of shares, where each share carries one vote and equal rights to the Company's assets and profits. The Company has overtime issued new shares and stock option programs and in February 2020 an extraordinary general meeting was held where a decision was taken to issue a maximum of 2 500 000 employee warrants to key employees of the Company. The period for exercising the employee stock warrants will run from 1 March 2023 to 31 March 2023. The employee warrants were granted gratuitously and costs of 480 TSEK have been recognized in the second quarter closing, representing the YTD cost 2021.

In December 2020, the Board of Directors decided on a directed share issue of initially SEK 41 294 000 and an additional SEK 33 706 000 after approval by an Extraordinary General Meeting held in January 2021. Through the issue, which comprised 10 000 000 shares at a subscription price of 7.50 SEK, the Company received 75 000 TSEK before issue costs.



Largest Shareholders

30 JUNE 2021	HOLDINGS	PERCENT
ADMA FÖRVALTNINGS AB	15 500 000	23.82%
SWEDBANK ROBUR MICROCAP	5 000 000	7.69%
FÖRSÄKRINGSAKTIEBOLAGET, AVANZA PENSION	4 774 960	7,34%
CBLDN-UBS FINANCIAL SERVICES INC	4 189 739	6.44%
HANDELSBANKEN MICROCAP SVERIGE	3 200 000	4.92%
FÖRSÄKRINGSAKTIEBOLAGET SKANDIA (PUBL)	2 546 835	3.91%
FE SMÅBOLAG SVERIGE	1 800 000	2.77%
EUROSUND AB	1 581 036	2.43%
POURSAMAD, AMIR	1 520 095	2.34%
RÜLF, SEMMY	1 015 058	1.56%
TOTAL	41 127 723	63.22%
OTHER SHAREHOLDERS	23 931 432	36.78%
TOTAL	65 059 155	100.00%

Source: Euroclear



Risk factors

An investment in securities is associated with risk. Dignitana's activities are affected, and may be affected, by several factors which cannot be completely controlled by the Company. There are risks both in terms of circumstances attributable to Dignitana and those which have no specific connection with the Company.

The non-definitive list of the Company's risks pertains, but is not limited, to: Patents, key personnel, growth management, management, restructuring, development costs, competitors, dependence on individual customers, customers, authorization and registration, chemotherapy without side effects, alternative cancer treatment methods, distributors and manufacturers, profitability and future capital requirements, political risk, pandemic risks, regulatory or change of laws, disputes and currency risks.

Risks related to COVID-19

The outbreak of COVID-19 in the spring of 2020 has affected the Company's opportunities to reach customers but also customers' ability to offer scalp cooling as a form of treatment. The Company has therefore been impacted financially, although it is not possible to make a full assessment.

The Board is ultimately responsible for managing and monitoring these risks. Ongoing management is delegated to the CEO, who in turn reports to the Board.

For a detailed explanation of these risk factors view the 2020 Annual Report posted at

<https://dignitana.com/investor-relations/financial-reports/>

Other information

Forward-looking statements

This report may contain statements, estimates or projections that constitute "forward-looking statements". Generally, the words "believe", "expect", "intend", "estimate", "anticipate", "project", "will" and similar expressions identify forward-looking statements, which generally are not historical in nature. Forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from the Dignitana historical experience or future projects.

Accounting principles

The consolidated financial statements comprise of Dignitana AB and its subsidiaries Dignitana Inc, and Dignitana Srl.

This interim report is prepared in accordance with Swedish GAAP, BFN 2012:1 (K3). The accounting policies remain unchanged compared with the preceding year and are the same principles that were applied for the Annual Report 2020.

Financial statements are presented in SEK, the functional currency of Dignitana AB. Assets and liabilities are translated and presented at the closing rate and the Income statement is translated and presented at period average exchange rates.

For a detailed explanation of accounting principles view the 2020 Annual Report posted at

<https://dignitana.com/investor-relations/financial-reports/>

This Interim Report has not been reviewed by the Group's Auditors.

Board assurance

The Board of Directors and Chief Executive Officer declare that this Interim Report provides a fair view of the Company's operations, financial position and results, and describes material risks and uncertainties facing the Company.

Dignitana AB

Corporate Registration Number: 556730-5346

Lund, 19 August 2021

Dignitana AB (publ) Board of Directors

Klas Arildsson
Chairman of the Board

William Cronin
Board member and CEO

Richard Dilorio
Board member

Lina Karlsson
Board member

Christian Lindgren
Board member

Ljubo Mrnjavac
Board member

Income Statement – Dignitana Group, TSEK

DIGNITANA GROUP	Q2 2021	Q2 2020	Q1-Q2 2021	Q1-Q2 2020	Full year 2020
Operating Income					
Net sales	14 038	11 423	27 203	22 816	46 629
Other operating income	3 136	452	4 128	1 537	3 327
Total Operating Income	17 174	11 875	31 331	24 353	49 956
Operating expense					
Goods for Resale	-4 700	-1 576	-9 961	-5 575	-16 921
Operating expense	-10 335	-7 262	-16 378	-17 302	-29 870
Personnel expense	-7 946	-6 803	-14 551	-13 453	-28 280
Depreciation and amortization of tangible and intangible assets	-2 972	-3 964	-6 278	-7 683	-20 764
Other operating expenses	-633	-1 300	-707	-1 851	-4 822
	-26 586	-20 905	-47 875	-45 864	-100 656
Operating profit (loss)	-9 412	-9 030	-16 544	-21 511	-50 700
Result from financial investments					
Other Interest income and similar items	23	0	79	32	1
Interest expenses and similar items	-271	-498	-859	-804	-2 264
	-248	-498	-780	-772	-2 263
Profit after financial items	-9 660	-9 528	-17 324	-22 283	-52 963
Profit before tax	-9 660	-9 528	-17 324	-22 283	-52 963
Tax on profit for the period	0	0	0	0	0
Results for the Period	-9 660	-9 528	-17 324	-22 283	-52 963
Average number of shares before and after dilution	65 059 155	55 059 155	62 812 113	55 059 155	60 565 070
Earnings per share before and after dilution, SEK	-0,15	-0,17	-0,28	-0,40	-0,96

Balance Sheet – Dignitana Group, TSEK

DIGNITANA GROUP	2021-06-30 2021	2020-06-30 2020	2020-12-31 2020
ASSETS			
FIXED ASSETS			
Intangible assets			
Capitalized expenses for development	13 537	19 193	16 233
	13 537	19 193	16 233
Tangible assets			
Equipment, tools and installations	28 836	29 203	27 501
	28 836	29 203	27 501
Total Fixed Assets	42 373	48 396	43 734
CURRENT ASSETS			
Inventories and similar			
Finished goods and goods for resale	6 695	9 583	7 455
	6 695	9 583	7 455
Current Receivables			
Accounts Receivable	5 826	4 018	5 435
Current Tax Assets	87	21	61
Other Current Receivables	917	1 218	1 071
Prepaid expenses and accrued income	1 680	2 572	1 363
	8 510	7 829	7 930
Cash and Bank Balances	36 333	7 484	78 770
Total Current Assets	51 538	24 896	94 155
Total Assets	93 911	73 292	137 889
EQUITY AND LIABILITIES			
Equity			
Share Capital	6 506	55 059	6 057
Unregistered share capital	0	0	449
Ongoing new issue	0	0	33 256
Other contributed capital	222 692	153 474	189 436
Other equity including profit for the year	-169 687	-174 419	-151 562
Total Equity	59 511	34 114	77 636
Provisions			
Other provisions	18	0	18
	18	0	18
Long Term Liabilities			
Other long term liabilities	11 834	5 851	1 661
Total Long Term Liabilities	11 834	5 851	1 661
Current Liabilities			
Liabilities to credit institutions	4 473	10 628	7 968
Accounts payable	7 997	10 323	13 327
Other current liabilities	967	4 177	23 737
Accrued expenses and deferred income	9 111	8 199	13 541
Total current liabilities	22 548	33 327	58 573
Total liabilities	34 382	39 178	60 235
Total Equity and Liabilities	93 911	73 292	137 889

Changes in Equity – Dignitana Group, TSEK

	Sharecapital	Other contributed capital	Retained earnings, incl. net loss for the year	Total equity
Opening equity on 1/1/2020	55 059	153 067	-153 023	55 103
New share issue	551	40 744		41 294
Ongoing new share issue	449	33 256		33 706
Reduction of share capital	-49 553		49 553	0
Issue expenses		-4 564		-4 564
Issue of warrants		189		189
Option program 2020			960	960
Net loss for the year			-52 963	-52 963
"Change in translation difference relating to subsidiaries"			3 912	3 912
Closing equity on 12/31/2020	6 506	222 692	-151 562	77 636
Net loss for the period			-17 324	-17 324
Option program 2020			480	480
"Change in translation difference relating to subsidiaries"			-1 281	-1 281
Closing equity on 06/30/2021	6 506	222 692	-169 687	59 511

Statement of Cash Flows – Dignitana Group, TSEK

DIGNITANA GROUP	Q2 2021	Q2 2020	Q1-Q2 2021	Q1-Q2 2020	Full year 2020
Operating activities					
Profit after financial investments	-9 660	-9 528	-17 324	-22 283	-52 963
Adjustments for items not affecting cash flows, etc	883	3 964	3 980	7 683	26 789
Tax paid	-80	306	-90	293	253
Cash flow from operating activities before changes in working capital	-8 857	-5 258	-13 434	-14 307	-25 921
Cash flow from changes in working capital					
Change in inventories	-138	-781	709	-181	-1 509
Change in other current receivables	162	-871	-176	-809	-1 214
Change in other current liabilities	-5 575	5 569	-10 204	3 794	7 341
Cash flows from operating activities	-14 408	-1 341	-23 105	-11 504	-21 303
Investing activities					
Investments in intangible assets	0	83	0	-152	-739
Proceeds from sale of intangible assets	0	0	0	0	0
Investments in tangible assets	-2 807	-3 627	-4 907	-11 113	-19 665
Cash flows from investing activities	-2 807	-3 544	-4 907	-11 265	-20 404
Financing activities					
New share issue	0	0	0	0	75 000
Issue expenses	0	218	0	218	-170
Liabilities to credit institutions	0	189	0	189	189
Options issued	0	0	0	0	20 000
New loans	0	2 328	0	0	3 487
Repaid loans	0	0	-20 000	0	0
Change in long term liabilities	8 507	0	6 227	9 348	0
Cash flow from financial activities	8 507	2 735	-13 773	9 755	98 506
Cash flow for the period	-8 708	-2 150	-41 786	-13 014	56 799
Cash and cash equivalents at beginning of period					
Cash and cash equivalents at beginning of period	44 366	8 768	78 770	19 433	19 433
Exchange-rate differences in cash and cash equivalents					
Exchange-rate differences in cash and cash equivalents	675	866	-651	1 065	2 538
Cash and cash equivalents at end of period	36 333	7 484	36 333	7 484	78 770

Income Statement – Dignitana AB, Parent Company, TSEK

DIGNITANA GROUP	Q2 2021	Q2 2020	Q1-Q2 2021	Q1-Q2 2020	Full year 2020
Operating Income					
Net sales	9 648	7 600	18 660	15 346	31 324
Other operating income	8	620	988	1 705	3 448
Total Operating Income	9 656	8 220	19 648	17 051	34 772
Operating expense					
Goods for Resale	-1 620	-1 021	-4 412	-2 999	-10 257
Operating expense	-4 589	-5 547	-7 114	-14 991	-26 372
Personnel expense	-4 070	-477	-7 636	-1 019	-2 301
Depreciation and amortization of tangible and intangible assets	-2 920	-3 891	-6 168	-7 535	-20 483
Other operating expenses	-595	-1 298	-595	-1 842	-4 510
	-13 794	-12 234	-25 925	-28 386	-63 923
Operating profit (loss)	-4 138	-4 014	-6 277	-11 335	-29 152
Result from financial investments					
Other Interest income and similar items	23	0	79	0	0
Interest expenses and similar items	-62	-107	-424	-122	-918
	-39	-107	-345	-122	-918
Profit after financial items	-4 177	-4 121	-6 622	-11 457	-30 069
Profit before tax	-4 177	-4 121	-6 622	-11 457	-30 069
Tax on profit for the period	0	0	0	0	0
Results for the Period	-4 177	-4 121	-6 622	-11 457	-30 069

Balance Sheet – Dignitana AB, Parent Company, TSEK

DIGNITANA AB, PARENT COMPANY	2021-06-30 2021	2020-06-30 2020	2020-12-31 2020
ASSETS			
FIXED ASSETS			
Intangible assets			
Capitalized expenses for development	13 512	19 162	16 207
	13 512	19 162	16 207
Tangible assets			
Equipment, tools and installations	28 619	28 789	27 223
	28 619	28 789	27 223
Financial assets			
Participations in group companies	522	522	522
Receivable from group companies	425	473	409
	947	995	931
Total Fixed Assets	43 078	48 947	44 361
CURRENT ASSETS			
Inventories and similar			
Finished goods and goods for resale	5 022	8 880	6 143
	5 022	8 880	6 143
Current Receivables			
Accounts Receivable	1 264	892	1 775
Receivables from group companies	30 567	7 740	18 207
Current Tax Assets	87	21	61
Other Current Receivables	761	1 013	911
Prepaid expenses and accrued income	864	609	536
	33 543	10 275	21 490
Cash and Bank Balances	30 488	1 857	76 505
Total Current Assets	69 053	21 012	104 138
Total Assets	112 131	69 959	148 499
EQUITY AND LIABILITIES			
Equity			
Restricted equity			
Share Capital	6 506	55 059	6 057
Unregistered share capital	0	0	449
Fund for development expenses	13 398	17 202	15 631
	19 904	72 261	22 137
Non-restricted equity			
Share premium reserves	222 692	153 474	222 692
Other non-restricted equity	-131 676	-154 963	-103 839
Results for the period	-6 622	-11 457	-30 069
	84 394	-12 946	88 784
Total Equity	104 298	59 315	110 921
Current Liabilities			
Accounts payable	3 078	6 160	8 620
Current payable to group company	0	0	0
Other current liabilities	121	185	20 120
Accrued expenses and deferred income	4 634	4 299	8 838
Total current liabilities	7 833	10 644	37 578
Total liabilities	7 833	10 644	37 578
Total Equity and Liabilities	112 131	69 959	148 499

Financial calendar

18 November 2021	Q3 Quarterly Report
17 February 2022	2020 Year End Report

All financial reports are available at
www.dignitana.com/investor-relations/financial-reports/

Contact information

Dignitana AB

Träktörgränden 3, 226 60 Lund
+46 (0) 46-16 30 90
info@dignitana.se
investorrelations@dignitana.com
www.dignitana.se

Certified Adviser

Redeye AB
+46 8 121 576 90
certifiedadviser@redeye.se
www.redeye.se